NCT04104438View on ClinicalTrials.gov

Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant

PHASE4CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

January 15, 2021

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions
Asses Immunosuppression Modulation on Renal Recovery Post LT
Interventions
DRUG

Basiliximab 20 MG

Basiliximab induction followed by tacrolimus, corticosteroids and mycophenolic acid with a switch to everolimus by post operative day 30

Trial Locations (1)

90095

UCLA Medical Center, Los Angeles

All Listed Sponsors
lead

Fady M Kaldas, M.D., F.A.C.S.

OTHER

NCT04104438 - Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant | Biotech Hunter | Biotech Hunter